Managing MS During COVID-19: Expert Consensus

Expert Consensus and Narrative Review on the Management of Multiple Sclerosis in the Arabian Gulf in the COVID-19 Era: Focus on Disease-Modifying Therapies and Vaccination Against COVID-19

A group of Arabian Gulf neurologists developed consensus recommendations on managing relapsing MS (RMS) during COVID-19. MS is generally not linked to severe COVID-19 outcomes, except in patients with advanced disability. DMTs like interferon-β, teriflunomide, and cladribine are considered safe, while therapies like anti-CD20 agents carry intermediate risks. Patients on DMTs should continue treatment, receive COVID-19 vaccines, and delay new high-risk therapies until vaccination is complete. These guidelines balance MS management with pandemic-related risks, ensuring optimal care.